Appendiceal Cancer: Causes, Symptoms, Diagnosis and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Appendiceal neoplasms are rare malignancies originating from the vermiform appendix, with an overall incidence of approximately 1-2 cases per 100,000 population per year. They are far less common than colorectal cancer but display greater histological diversity. The most prevalent histological subtype is well-differentiated neuroendocrine tumor (NET, formerly carcinoid tumor), which accounts for approximately 50% of appendiceal tumors, followed by low-grade mucinous appendiceal neoplasm (LAMN, approximately 24%), goblet cell adenocarcinoma (GCA, approximately 10%), and colonic-type adenocarcinoma (approximately 11%). Appendiceal tumors are frequently discovered incidentally during appendectomy performed for presumed appendicitis — histological examination of the appendiceal specimen reveals the unexpected neoplasm in approximately 0.5-1% of all appendectomies. The most clinically significant complication of appendiceal mucinous neoplasms is pseudomyxoma peritonei (PMP) — a syndrome arising from perforation or mucin leakage of a mucinous appendiceal tumor, seeding the peritoneal cavity with mucin-producing cells that progressively accumulate mucin (the 'jelly belly' phenomenon). PMP is life-threatening without specialized surgical treatment. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) at specialized peritoneal oncology centers is the cornerstone of curative treatment for PMP and peritoneal-spread appendiceal adenocarcinoma.

Each appendiceal tumor subtype has distinct molecular and cellular origins. Appendiceal well-differentiated NETs (carcinoids): arise from enterochromaffin (Kulchitsky) cells — specialized serotonin-producing neuroendocrine cells interspersed throughout the appendiceal mucosa; most are sporadic; MEN1 syndrome (menin gene germline mutation on chromosome 11q13) predisposes to small bowel and appendiceal NETs with a higher rate of multifocality; NF1 also marginally increases NET risk. Low-grade mucinous appendiceal neoplasm (LAMN): arise from columnar mucinous epithelium; molecular alterations include KRAS mutations (codon 12, approximately 50%) and GNAS mutations (Gs-alpha subunit — approximately 20%), both driving mucinous differentiation and mucin overproduction; LAMNs may perforate or leak, seeding the peritoneum with mucin-producing cells to produce PMP. Goblet cell adenocarcinoma (GCA): mixed neuroendocrine-adenocarcinoma features; arises from pluripotent stem cells within crypts; more aggressive behavior than pure NETs; key molecular driver is a mixed glandular and neuroendocrine phenotype. Colonic-type adenocarcinoma: harbors molecular alterations closely paralleling right-sided colorectal adenocarcinoma — KRAS mutations in approximately 50%, RAS/RAF pathway activation, BRAF V600E in occasional cases, MMR gene mutations (Lynch syndrome-associated MSI-H tumors in approximately 10-15% of appendiceal adenocarcinomas). Hereditary risk syndromes: Lynch syndrome (germline MLH1, MSH2, MSH6, PMS2 mutations) substantially increases appendiceal adenocarcinoma risk; FAP (APC germline mutation) confers modest appendiceal adenocarcinoma risk.

The clinical presentation of appendiceal tumors is heavily influenced by tumor subtype, size, and whether peritoneal dissemination has occurred. Most appendiceal NETs smaller than 2 cm are entirely asymptomatic and are discovered as incidental pathological findings on histological examination of the appendectomy specimen removed for clinically presumed acute appendicitis. Acute appendicitis-like presentation: right lower quadrant pain, nausea, vomiting, anorexia, and low-grade fever indistinguishable from uncomplicated appendicitis — the underlying neoplasm is not suspected until pathological examination; a palpable or endoluminal appendiceal mass may predispose to appendiceal luminal obstruction mimicking appendicitis. Pseudomyxoma peritonei (PMP) — clinical features reflecting progressive peritoneal mucin accumulation: insidious progressive abdominal distension over months to years; abdominal bloating with fullness and early satiety from mucin displacing intraperitoneal organs; bilateral adnexal or ovarian masses on pelvic examination or imaging from mucin infiltrating the ovaries (frequently misdiagnosed as primary ovarian cancer — approximately 20% of PMP cases initially receive incorrect ovarian cancer diagnosis); bowel obstruction symptoms (colicky abdominal pain, absolute constipation, vomiting) as mucin encases bowel loops; gelatinous quality to abdominal distension ('jelly belly'). Carcinoid syndrome: occurs only in appendiceal NETs larger than 2 cm with established liver metastases actively secreting serotonin into systemic circulation — episodic cutaneous flushing (face, neck, and upper chest), watery secretory diarrhea, bronchospasm (wheezing), and right-sided cardiac valvular lesions (tricuspid and pulmonary valve thickening from serotonin-induced fibrosis). Constitutional features of advanced disease: unintentional weight loss, cachexia, and fatigue.

For tumors discovered incidentally at appendectomy, histopathological examination by an experienced GI pathologist is the foundation of diagnosis — pathological assessment must include: tumor histological subtype (NET, LAMN, GCA, or adenocarcinoma); tumor size (critical for NET management — the 1 cm and 2 cm thresholds); Ki-67 proliferation index (NETs: G1 = Ki-67 below 2%, G2 = 3-20%, G3 = above 20%); margin status; lymphovascular and perineural invasion; mesoappendix invasion depth; and evidence of perforation or mucin extrusion (critical for PMP risk assessment). CT abdomen/pelvis with contrast: standard imaging for staging, peritoneal assessment, hepatic metastasis evaluation, and pelvic organ involvement — calcified peritoneal or omental nodules are characteristic of PMP (mucinous implants with dystrophic calcification). MRI abdomen/pelvis: superior for hepatic metastasis characterization and complex peritoneal assessment. 68Ga-DOTATATE PET-CT: radiolabeled somatostatin analogue scan — highly sensitive and specific for detecting well-differentiated SSTR2-expressing NETs; recommended for all appendiceal NETs above 2 cm or with lymph node involvement. PET-FDG: for high-grade G3 NETs and adenocarcinoma. Tumour markers: chromogranin A (CgA) and 24-hour urine 5-HIAA for functional NETs; serum CEA and CA 19-9 for mucinous adenocarcinoma and LAMN. Peritoneal Cancer Index (PCI) score: quantifies peritoneal tumor burden in PMP and adenocarcinoma — scores range from 0-39 based on tumor distribution across 13 abdominal regions; PCI below 20 generally indicates CRS/HIPEC candidacy; PCI above 20 indicates systemic chemotherapy or palliative approach. MSI/MMR status and comprehensive NGS panel for adenocarcinoma.

Management is highly tailored to appendiceal tumor subtype, size, grade, and extent of peritoneal involvement. Appendiceal NETs ≤1 cm: laparoscopic or open appendectomy is curative (>99% 5-year disease-specific survival); no additional workup is required. NETs 1-2 cm: appendectomy is generally adequate; right hemicolectomy is recommended if mesoappendix invasion exceeds 3 mm, vascular invasion is present, Ki-67 is above 2%, or the appendiceal margin is involved. NETs above 2 cm (metastatic risk approximately 30-40%): right hemicolectomy with regional lymph node dissection (minimum 12 nodes); 68Ga-DOTATATE PET staging. Systemic therapy for metastatic appendiceal NETs: long-acting octreotide LAR (20-30 mg IM monthly) or lanreotide 120 mg SC for somatostatin receptor-positive disease (CLARINET trial: 32-month median PFS vs 18 months placebo); 177Lu-DOTATATE (Lutathera) PRRT for SSTR2-positive progressive disease (NETTER-1 trial: 65.2% PFS at 20 months vs 10.8%); everolimus for poorly differentiated or SSTR-negative disease. Goblet cell adenocarcinoma: right hemicolectomy; TC (taxol + cyclophosphamide) or FOLFOX adjuvant chemotherapy. Mucinous adenocarcinoma: right hemicolectomy for localized disease; FOLFOX (oxaliplatin 85 mg/m2 + leucovorin 400 mg/m2 + 5-FU 2400 mg/m2 over 46h, every 2 weeks) or FOLFIRI for metastatic disease. KRAS wild-type: cetuximab or panitumumab by analogy with colorectal cancer. MSI-H: pembrolizumab. Pseudomyxoma peritonei: cytoreductive surgery (CRS — peritonectomy of all involved peritoneal surfaces plus visceral resection as required, including bilateral oophorectomy) combined with HIPEC (mitomycin C 35 mg/m2 at 42°C for 90 minutes, or oxaliplatin 460 mg/m2) at a specialized peritoneal oncology center — 10-year OS of 60-80% for PMP with low PCI. Systemic bevacizumab plus FOLFOX/FOLFIRI for PMP not amenable to CRS/HIPEC.

Prognosis for appendiceal neoplasms varies dramatically by histological subtype and stage. Appendiceal well-differentiated NETs below 1 cm carry essentially 100% disease-specific 5-year survival — appendectomy alone is curative. NETs 1-2 cm carry 5-year survival of approximately 95-98% with appropriate surgical management. NETs above 2 cm with regional metastases carry 5-year survival of approximately 65-75%; distant liver metastases reduce survival to approximately 50-65% at 5 years, though somatostatin analogue therapy and PRRT extend survival meaningfully. Goblet cell adenocarcinoma (GCA) carries intermediate prognosis — 5-year survival approximately 60-70% for localized disease, falling to approximately 30-40% with peritoneal spread. Colonic-type adenocarcinoma of the appendix has 5-year survival comparable to right-sided colorectal cancer — approximately 60-70% for localized and node-negative disease, falling with advancing stage. Pseudomyxoma peritonei (PMP) treated with CRS plus HIPEC at specialized centers achieves 5-year overall survival of approximately 80-85% and 10-year survival of approximately 60-70% for low-grade disease with a peritoneal cancer index below 20. High-grade PMP carries significantly worse prognosis, with 5-year survival of approximately 40-50% even with CRS/HIPEC. The most critical prognostic factors for PMP are tumor grade, completeness of cytoreduction (CC-0 vs CC-1/2), and peritoneal cancer index at surgery. Recovery after CRS/HIPEC is prolonged, with median hospital stay of 10-14 days and functional recovery over 3-6 months. Recurrence after CRS/HIPEC for PMP occurs in approximately 30-40% of patients within 5 years and may be amenable to repeat intervention in carefully selected patients at specialized peritoneal oncology centers.

There are no established preventive measures for most appendiceal tumors, as they are predominantly sporadic. Lynch syndrome and FAP patients are at elevated risk for appendiceal adenocarcinoma and should include gastrointestinal surveillance in their hereditary cancer management programme. When a mucinous appendiceal neoplasm (LAMN) is identified at pathology — even after appendectomy for presumed appendicitis — referral to a specialist centre for assessment of peritoneal spread is essential, as occult PMP may be treatable at an early stage before massive mucin accumulation. Patients with carcinoid syndrome symptoms (flushing, diarrhoea) or new abdominal distension of uncertain cause should be evaluated promptly, as early peritoneal disease has better CRS/HIPEC outcomes than bulky established PMP.

Progressive unexplained abdominal distension — particularly in an otherwise well individual, with a gelatinous quality to abdominal contents on imaging — should prompt urgent evaluation for PMP. Women diagnosed with bilateral ovarian masses should have appendiceal origin considered and excluded, as PMP from appendiceal mucinous neoplasms frequently mimics ovarian cancer on imaging. Following appendectomy, any report of a mucinous or carcinoid tumor in the appendiceal specimen requires prompt follow-up with a surgical oncologist rather than assuming routine post-appendectomy care is sufficient. Symptoms of carcinoid syndrome — episodic facial flushing, watery diarrhoea, and wheezing — in a patient with a history of appendiceal neoplasm indicate likely liver metastases with systemic serotonin secretion and require oncological evaluation. All pathology reports from appendectomies should be reviewed to ensure appropriate management of unexpected neoplastic findings.